These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31030994)

  • 1. Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer.
    Dello Russo C; Gagliardi D; Ramlogan R; Navarra P
    Clin Ther; 2019 May; 41(5):982-991. PubMed ID: 31030994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the first-line treatment of non-small cell lung cancer.
    Ninomiya K; Hotta K
    Expert Opin Biol Ther; 2018 Oct; 18(10):1015-1021. PubMed ID: 30207786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
    Peters S; Kerr KM; Stahel R
    Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
    Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
    Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions.
    Qin Q; Li B
    J Cancer Res Ther; 2019; 15(4):743-750. PubMed ID: 31436226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Hersom M; Jørgensen JT
    Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
    Liu SY; Wu YL
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1355-1364. PubMed ID: 33044117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in lung cancer: current evidence and future perspectives.
    Palumbo G; Carillio G; Manzo A; Montanino A; Sforza V; Costanzo R; Sandomenico C; Manna C; Luca G; Piccirillo MC; Daniele G; Cecio R; Botti G; Totaro G; Muto P; Picone C; Esposito G; Normanno N; Morabito A
    Future Oncol; 2019 Oct; 15(29):3327-3336. PubMed ID: 31432705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
    N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for the treatment of non-small cell lung cancer.
    Muller M; Schouten RD; De Gooijer CJ; Baas P
    Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for the treatment of non-small cell lung cancer.
    Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.